By T. M. Fliedner (auth.), Prof. Dr. Hans-Dieter Flad, Prof. Dr. Christian Herfarth, Dr. Michael Betzler (eds.)
The notion of immunologic responses opposed to tumors is at present lower than excessive scrutiny during the international. The proof for the life of tumor-specific transplantation antigens (TSTA) and particular immune reactions to them in experimental animals is overwhelming. The on hand info referring to human tumors are debatable. the cause of this can be in part that antigens detectable on human tumors by way of in vitro assays haven't been biologically characterised. In different phrases, we don't recognize if the antigens on human tumors are appearing because the ambitions for immunologically mediated rejection techniques in vivo. It used to be the aim of this workshop to deliver experimental tumor immunologists and scientific oncologists jointly that allows you to expose proof and boundaries in tumor immunology. Clinicians have been to benefit how shaky the floor turns into as soon as the experimentalist appears to be like past the sting of the mouse cage. Tumor biologists heard the clinicians' pressing cry for managed randomized trials of immunotherapy which hence displays basically that immunotherapy in its current shape with out wisdom of dose-effect-relationship doesn't paintings. no one might deny that the matter of human melanoma smells of immunology, yet for the reason that we're as regards to to style it the fundamental factor could be diversified. In different phrases one could examine current really at immunological epiphenomena than at mechanisms of tumor immul1lty working in vivo. This challenge was once between others a significant factor of this workshop.